Papers/PMID:40490846
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.
International journal of cancer2025The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid — no detected effect on adverse event occurrence (oral or enteral supplement)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Overall, there were no significant differences in the incidence, type, or severity of adverse effects reported in the placebo or DHA group.”
Quoted verbatim from Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.. - Study
- RCT
- Duration
- 4 months
- Dose
- 4.4 g/day DHA-enriched algae triacylglycerol (11 x 400 mg capsules/day), oral, concurrent with 6 cycles (18 weeks) of neoadjuvant chemotherapy
- Population
- women with stage I-III non-metastatic breast cancer undergoing neoadjuvant chemotherapy
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.2025PMID:40490846Industry fundedPermalink